Pfizer gets USFDA nod for potential blockbuster heart drug Tafamidis Medical Dialogues Bureau7 May 2019 4:15 AMPfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under...